Unicycive Therapeutics (UNCY) Stock Forecast & Price Target

Unicycive Therapeutics is attractive because its lead asset, oxylanthanum carbonate, has already cleared the key clinical hurdle, with the FDA raising no efficacy or safety concerns and instead focusing on remediable CMC issues tied to the original vendor. The new third-party manufacturer has a clean FDA inspection record, completed 12-month stability studies, and included bridging data, while the company still has $61.4M in cash and marketable securities and expects runway into 2H27. If approved around end of 1Q27, TDAPA could begin in July 2027, giving OLC a meaningful reimbursement tailwind as the only phosphate binder outside the bundle through mid-2029, which supports the positive outlook.

Unicycive Therapeutics is burdened by years of operating losses, no product revenue, and a business model that still depends on a successful OLC launch before any meaningful cash generation can occur. Its financing profile is also weak, with about $61M in cash at the end of 2Q 2026 and $102M in warrant-linked capital commitments that could add up to 15.8M shares of dilution, while profitability is not expected on a continuing basis until 2027. The thesis is further pressured by binary FDA and manufacturing risks, possible reimbursement friction in the ESRD PPS environment, and uncertain commercial uptake against generic sevelamer, Fosrenol, and other approved phosphate binders.